Drag a card by its title · ⚙ to size, swap or remove

The company

ClearSign Technologies Corporation

CLIR · Nasdaq

Health CareLife-science toolsNot moving yet

CLIR stood above a rising 150-day average in 9 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 42.8% below that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 38
Industry in uptrend: 52% +4 in 4 wk
Insider buys, 12 months: $3.6M
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 24 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.

17 Apr – 16 Oct

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4

Sale orders, 12 months0

Buyers · sellers2 · 0

Who	Did	Shares	Traded
John M. Pasquesi10% owner	bought	500,000at $3.54	22 Jul 2026filed 24 Jul 2026
Gil Todd SilvaDirector	bought	1,000at $5.32	23 Apr 2026filed 27 Apr 2026
Gil Todd SilvaDirector	bought	1,000at $5.25	23 Apr 2026filed 27 Apr 2026
Gil Todd SilvaDirector	bought	2,000at $4.20	17 Mar 2026filed 19 Mar 2026
Gil Todd SilvaDirector	bought	2,000at $4.36	16 Mar 2026filed 19 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders24+6 on the quarter

New · exited7 · 1

Reported value$1.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026	105,429$387K	00.0%
SIMON QUICK ADVISORS, LLCunchanged · filed 28 Jul 2026	60,314$221K	00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026	51,457$189K	-6,226−10.8%
Beacon Pointe Advisors, LLCunchanged · filed 18 Aug 2026	27,173$100K	00.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026	23,460$86K	00.0%
HighTower Advisors, LLCadded · filed 5 Aug 2026	22,662$83K	+9,982+78.7%
CITADEL ADVISORS LLCnew · filed 14 Aug 2026	20,565$75K	+20,565
BlackRock, Inc.unchanged · filed 7 Aug 2026	19,503$72K	00.0%
DDD Partners, LLCunchanged · filed 5 Aug 2026	12,000$44K	00.0%
NORTHERN TRUST CORPnew · filed 13 Aug 2026	10,080$37K	+10,080

31 Mar 2023 – 30 Jun 2026

News

ClearSign Technologies: ClearSign Receives Order for M1 Series Burner from Tulsa Heaters Midstreamfinanznachrichten.de · 1 Oct 2026 ClearSign Technologies: ClearSign and Kern Energy Selected for U.S. Department of Energy Industrial Technology Validation Programfinanznachrichten.de · 30 Sep 2026

Everyone who traded it

Anthony Digiandomenico Director · last 30 Sep 20260 · 0

Gil Todd Silva Director · last 30 Sep 20263 · 0

Larry Michael Saddler Director · last 30 Sep 20260 · 0

Lou Basenese Director · last 30 Sep 20260 · 0

John M. Pasquesi 10% owner · last 22 Jul 20261 · 0

Brent Hinds Chief Financial Officer · last 26 Feb 20260 · 0

Colin James Deller Chief Executive Officer · last 26 Feb 20260 · 0

David M. Maley Director · last 1 Jul 20250 · 0

Judith S. Schrecker Director · last 1 Jul 20250 · 0

Lacy Catharine De Director · last 1 Jul 20250 · 0

Princeton Opportunity Management Llc 10% owner · last 24 Jun 20241 · 0

Robert Thurston Hoffman, Sr. Director · last 1 Apr 20240 · 0

Same industry

OABI OmniAbLeading+65%

TXG 10x GenomicsLeading+60%

AVTR AvantorLeading+47%

ILMN IlluminaLeading+44%

RVTY RevvityLeading+37%

CRL Charles River Laboratories InternationalLeading+35%

MASS 908 DevicesLeading+31%

IQV IQVIA HoldingsLeading+27%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202538.8%

Operating profit marginFY 2025 · to 31 Dec 2025-182%

Free cash flow marginFY 2025 · to 31 Dec 2025-129%

Return on capital employedFY 2025 · to 31 Dec 2025-69.5%

Research spendFY 2025 · to 31 Dec 202538.7%

Revenue growthFY 2025 · to 31 Dec 2025257%

Share count trendFY 2025 · to 16 Mar 20261.5%

Cash and equivalentsFY 2025 · to 31 Dec 2025$9.2M

Free cash flowFY 2025 · to 31 Dec 2025−$4.7M

Analyst forecasts

No analyst forecasts yet.